Brokers Issue Forecasts for Oxford Biomedica’s FY2022 Earnings (OXBDF)

Oxford Biomedica (OTCMKTS:OXBDF) – Investment analysts at Jefferies Group issued their FY2022 earnings per share (EPS) estimates for Oxford Biomedica in a report issued on Friday. Jefferies Group analyst P. Welford anticipates that the company will earn $0.01 per share for the year.

How to Become a New Pot Stock Millionaire

Separately, ValuEngine cut shares of Oxford Biomedica from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd.

Oxford Biomedica stock traded down $0.02 during trading on Monday, reaching $0.17. 981,450 shares of the company’s stock traded hands, compared to its average volume of 145,269. Oxford Biomedica has a 52-week low of $0.06 and a 52-week high of $0.20.

TRADEMARK VIOLATION WARNING: This piece of content was reported by Markets Daily and is the property of of Markets Daily. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark laws. The legal version of this piece of content can be accessed at

Oxford Biomedica Company Profile

Oxford BioMedica plc, a biopharmaceutical company, researches, develops, and produces gene and cell therapy products for the treatment of ocular, neurodegenerative, and cancer diseases in Europe and rest of world. The company operates through Partnering and R&D segments. Its LentiVector platform technology integrates genes into non-dividing cells in the brain and the eye, as well as accommodates multiple therapeutic genes.

Receive News & Ratings for Oxford Biomedica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Biomedica and related companies with's FREE daily email newsletter.

Leave a Reply